Uloric (febuxostat) is a xanthine oxidase inhibitor for lowering uric acid in gout patients.

Takeda Ventures: A global investment firm specializing in technology and biopharmaceutical ventures.
Takeda Ventures, Inc. is the venture investment arm of Takeda, a global biopharmaceutical leader. Founded to drive innovation in technology and biopharmaceuticals, its core mission is to identify and invest in groundbreaking technologies and product concepts that can advance healthcare globally. The firm focuses on early-stage investments in companies developing novel therapeutics and platform technologies, aiming to foster advancements that align with Takeda's broader vision of improving patient health worldwide.
Notable affiliates of Takeda Ventures include its parent company, Takeda Pharmaceutical Company Limited, a renowned entity in the biopharmaceutical industry. The firm has made significant strides in supporting pioneering startups and technologies, contributing to the development of impactful medical treatments. Key achievements include successful investments in companies that have progressed to clinical trials and market launches. Overall, Takeda Ventures has established itself as a crucial player in the biopharmaceutical investment landscape, driving innovation and enhancing global healthcare outcomes.
Companies similar to Takeda include Crystalys Therapeutics, Taiho Pharmaceutical Co., PTC Therapeutics and Teva Pharmaceutical Industries.
Takeda was founded in 1781.
Takeda's headquarters is located in San Diego, CA, US.
Takeda's most recent funding round was for $19.8M (USD) in September 2016.
As of Sep 1, 2016, Takeda has raised a total of $57.8M (USD).
Takeda has 47,347 employees as of Feb 6, 2024.

PTC Therapeutics
ptcbio.com